#United States #New Orleans #ImmunityBio #FDA Warning #stock decline

Major Stock Decline for ImmunityBio

In a recent turn of events, ImmunityBio, Inc. (NasdaqGS: IBRX) has found itself at the center of a securities fraud class action lawsuit following a substantial drop in its stock price. Investors who purchased shares between January 19, 2026, and March 24, 2026, are particularly affected. The company’s shares plunged by 21% on March 24, 2026, driven primarily by a warning issued by the U.S. Food and Drug Administration (FDA) regarding misleading claims associated with one of its cancer therapies, Anktiva.

Background of the Incident

The FDA's warning letter, made public on March 24, stated that ImmunityBio’s promotional communications concerning Anktiva misrepresented the drug’s capabilities. Specifically, the FDA highlighted that the advertisements misleadingly suggested that Anktiva could cure and prevent all forms of cancer. This prompted concerns not just among investors but also for public health, as such messages may lead to false expectations among patients.

The immediate result of this disclosure was a significant dip in ImmunityBio's stock price, plummeting $1.98 to close at $7.42 per share. This decline raised alarms among shareholders and investors who may now face significant financial losses.

Legal Recourse for Investors

In light of these developments, Kahn Swick & Foti, LLC (KSF), a law firm specializing in securities litigation, has reached out to affected investors. Charles C. Foti, Jr., a former Attorney General of Louisiana and KSF partner, emphasized the importance of acting quickly. Investors have until May 26, 2026, to file lead plaintiff applications in the ongoing class action lawsuit against ImmunityBio. This lawsuit indicates that the firm believes there are grounds for holding the company and its executives accountable for failing to disclose critical information that may have influenced investor decisions.

The legal action has the potential to provide affected investors with an avenue for recovering their losses due to perceived mishandling and misrepresentation of the company's drug. Investors wishing to participate in the suit can consult KSF for guidance on their rights and next steps.

Implications for ImmunityBio

This situation raises serious questions about ImmunityBio's compliance with federal securities laws and how the company manages its public communication, especially regarding product efficacy. The fallout from this incident is likely to affect the company's reputation and could impact future investment opportunities. As the case progresses, it remains to be seen how ImmunityBio will address these allegations, both legally and publicly.

Conclusion

Investors are advised to stay informed about the developments in the ImmunityBio case, as it could set important precedents for how biotech companies disclose critical information to the public and investors alike. With regulatory scrutiny increasing, companies operating in this space must ensure that their communications are clear, accurate, and compliant with all legal standards to avoid similar repercussions in the future.